Abstract：
OBJECTIVE: Temporal bone squamous cell carcinoma (TBSCC) is a rare malignancy with poor prognosis, and optimal treatment for advanced cases is uncertain. Our systematic literature review aimed to assess 5-year survival outcomes for advanced TBSCC across different treatment modalities.
METHODS: EMBASE, Medline, PubMed, and Web of Science.
METHODS: A systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for articles published between January 1989 and June 2023.
RESULTS: The review yielded 1229 citations of which 31 provided 5-year survival data for TBSCC. The final analysis included 1289 patients. T classification data was available for 1269 patients and overall stage for 1033 patients. Data for 5-year overall survival (OS) was 59.6%. Five-year OS was 81.9% for T1/2 and 47.5% for T3/4 (P < .0001). OS for T1/T2 cancers did not significantly differ between surgery and radiation (100% vs 81.3%, P = .103). For advanced-stage disease (T3/T4), there was no statistical difference in OS when comparing surgery with postoperative chemoradiotherapy (CRT) (OS 50.0%) versus surgery with postoperative radiotherapy (XRT) (OS 53.3%) versus definitive CRT (OS 58.1%, P = .767-1.000). There was not enough data to assess the role of neoadjuvant CRT.
CONCLUSIONS: Most patients will present with advanced-stage disease, and nodal metastasis is seen in nearly 22% of patients. This study confirms the prognostic correlation of the current T classification system. Our results suggest that OS did not differ significantly between surgery and XRT for early stage disease, and combined treatment modalities yield similar 5-year OS for advanced cancers.
METHODS: EMBASE, Medline, PubMed, and Web of Science.
METHODS: A systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for articles published between January 1989 and June 2023.
RESULTS: The review yielded 1229 citations of which 31 provided 5-year survival data for TBSCC. The final analysis included 1289 patients. T classification data was available for 1269 patients and overall stage for 1033 patients. Data for 5-year overall survival (OS) was 59.6%. Five-year OS was 81.9% for T1/2 and 47.5% for T3/4 (P < .0001). OS for T1/T2 cancers did not significantly differ between surgery and radiation (100% vs 81.3%, P = .103). For advanced-stage disease (T3/T4), there was no statistical difference in OS when comparing surgery with postoperative chemoradiotherapy (CRT) (OS 50.0%) versus surgery with postoperative radiotherapy (XRT) (OS 53.3%) versus definitive CRT (OS 58.1%, P = .767-1.000). There was not enough data to assess the role of neoadjuvant CRT.
CONCLUSIONS: Most patients will present with advanced-stage disease, and nodal metastasis is seen in nearly 22% of patients. This study confirms the prognostic correlation of the current T classification system. Our results suggest that OS did not differ significantly between surgery and XRT for early stage disease, and combined treatment modalities yield similar 5-year OS for advanced cancers.
摘要：
目的：颞骨鳞状细胞癌（TBSCC）是一种罕见的恶性肿瘤，预后不良，对晚期病例的最佳治疗方法尚不确定。我们的系统文献综述旨在评估不同治疗方式的晚期TBSCC的5年生存结果。
方法：EMBASE，Medline,PubMed,和WebofScience。
方法：根据1989年1月至2023年6月发表的文章的系统评价和荟萃分析首选报告项目进行系统文献综述。
结果：该综述引用了1229篇，其中31篇提供了TBSCC的5年生存数据。最终分析包括1289名患者。T分类数据可用于1269例患者和1033例患者的总体阶段。5年总生存率(OS)数据为59.6%。T1/2和T3/4的五年OS分别为81.9%和47.5%(P<0.0001)。T1/T2癌症的OS在手术和放疗之间没有显着差异（100％vs81.3％，P=.103）。对于晚期疾病（T3/T4），比较手术与术后放化疗（CRT）（OS50.0％）与手术与术后放疗（XRT）（OS53.3％）与确定性CRT（OS58.1％，P=.767-1.000）。没有足够的数据来评估新辅助CRT的作用。
结论：大多数患者会出现晚期疾病，淋巴结转移在近22％的患者中可见。本研究证实了当前T分类系统的预后相关性。我们的结果表明，对于早期疾病，手术和XRT之间的OS没有显着差异，和联合治疗方式对晚期癌症产生相似的5年OS。
方法：EMBASE，Medline,PubMed,和WebofScience。
方法：根据1989年1月至2023年6月发表的文章的系统评价和荟萃分析首选报告项目进行系统文献综述。
结果：该综述引用了1229篇，其中31篇提供了TBSCC的5年生存数据。最终分析包括1289名患者。T分类数据可用于1269例患者和1033例患者的总体阶段。5年总生存率(OS)数据为59.6%。T1/2和T3/4的五年OS分别为81.9%和47.5%(P<0.0001)。T1/T2癌症的OS在手术和放疗之间没有显着差异（100％vs81.3％，P=.103）。对于晚期疾病（T3/T4），比较手术与术后放化疗（CRT）（OS50.0％）与手术与术后放疗（XRT）（OS53.3％）与确定性CRT（OS58.1％，P=.767-1.000）。没有足够的数据来评估新辅助CRT的作用。
结论：大多数患者会出现晚期疾病，淋巴结转移在近22％的患者中可见。本研究证实了当前T分类系统的预后相关性。我们的结果表明，对于早期疾病，手术和XRT之间的OS没有显着差异，和联合治疗方式对晚期癌症产生相似的5年OS。
